Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer

Activation of endogenous glucocorticoids by HSD11B1 inhibits the antitumor immune response in renal cancer

ABSTRACTAlthough immune-based therapies have revolutionized the management of cancer, novel approaches are urgently needed to improve their outcome. We investigated the role of endogenous steroids in the resistance to cancer immunotherapy, as these have strong immunomodulatory functions. Using a pub...

Full description

Bibliographic Details
Main Authors: Hélène Poinot, Eloïse Dupuychaffray, Grégoire Arnoux, Montserrat Alvarez, Jérémie Tachet, Ounss Ezzar, Jonathan Moore, Olivia Bejuy, Eulalia Olesti, Gioele Visconti, Víctor González-Ruiz, Serge Rudaz, Jean-Christophe Tille, Clarissa D. Voegel, Patrycja Nowak-Sliwinska, Carole Bourquin, Aurélien Pommier
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:OncoImmunology
Subjects:
Glucocorticoids
HSD11B1
immunotherapy
renal cancer
steroidogenesis
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2023.2286820

Internet

https://www.tandfonline.com/doi/10.1080/2162402X.2023.2286820

Similar Items